Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891848403> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W2891848403 abstract "e18258 Background: In the last decade, TFR was described as a side-effect associated with immunomodulatory agents IMiDs (thalidomide and lenalidomide), and as a specific condition to chronic lymphocytic leukemia (CLL). However, this phenomenon is seen with the use of new immunotherapy (checkpoints inhibitors) in solid tumors, in addition, cases of TFR were reported in advanced gynecologic, prostate cancer and lymphoid malignancies. TFR is defined as an increase of lesion size related to treatment which simulates disease progression. This phenomenon that occurs after initiating cancer therapy is poorly understood and incidence is under-estimated, since not captured by Recist. It has been suggested that TFR may be the results of immune system activation and may precede tumor shrinkage. TFR is associated with morbidity, severe cases were reported, some of them life-threatening or leading to death. So, early recognition and initial management of patients presenting with TFR, is critical. Methods: From 1985 to 2016, a search was performed in the Pubmed, ASCO and ASH abstracts to identify publications reporting TFR or pseudoprogression. Results: The incidence of all grades of TFR in CLL, ranged from 28% in a study to 58% in another trial. In CLL, painful lymph nodes and/or spleen enlargement were reported with a sudden onset after the first dose. Following initial progression (TFR), tumor response in patients treated beyond progression, was reported inmelanoma trials: 9.7% with ipilimumab, 10% with nivolumab, 6.7% and 12% with pembrolizumab, and in renal cell carcinoma 69% with nivolumab. Even if rare cases of life-threatening or fatal TFR were reported, symptoms are usually mild. While correct diagnosis and adequate management are critical, it is important to better recognize TFR, and avoid an effective treatment discontinuation. Some studies showed that treating patients beyond progression yielded tumor responses, considering TFR as predictive of response. Conclusions: Treatment with immunomodulatory agents is associated with TFR. This is likely to be misinterpreted as progression, hence the need to identify appropriate clinical benefit criteria and the use of immune-related RECIST (irRC) in prospective trials for a better understanding." @default.
- W2891848403 created "2018-09-27" @default.
- W2891848403 creator A5012233810 @default.
- W2891848403 date "2017-05-20" @default.
- W2891848403 modified "2023-09-23" @default.
- W2891848403 title "Tumor flare reaction (TFR) in cancer treatments: A systematic review." @default.
- W2891848403 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e18258" @default.
- W2891848403 hasPublicationYear "2017" @default.
- W2891848403 type Work @default.
- W2891848403 sameAs 2891848403 @default.
- W2891848403 citedByCount "4" @default.
- W2891848403 countsByYear W28918484032019 @default.
- W2891848403 countsByYear W28918484032020 @default.
- W2891848403 crossrefType "journal-article" @default.
- W2891848403 hasAuthorship W2891848403A5012233810 @default.
- W2891848403 hasConcept C121608353 @default.
- W2891848403 hasConcept C126322002 @default.
- W2891848403 hasConcept C143998085 @default.
- W2891848403 hasConcept C502942594 @default.
- W2891848403 hasConcept C71924100 @default.
- W2891848403 hasConceptScore W2891848403C121608353 @default.
- W2891848403 hasConceptScore W2891848403C126322002 @default.
- W2891848403 hasConceptScore W2891848403C143998085 @default.
- W2891848403 hasConceptScore W2891848403C502942594 @default.
- W2891848403 hasConceptScore W2891848403C71924100 @default.
- W2891848403 hasLocation W28918484031 @default.
- W2891848403 hasOpenAccess W2891848403 @default.
- W2891848403 hasPrimaryLocation W28918484031 @default.
- W2891848403 hasRelatedWork W2006745473 @default.
- W2891848403 hasRelatedWork W2015884113 @default.
- W2891848403 hasRelatedWork W2024483482 @default.
- W2891848403 hasRelatedWork W2025555311 @default.
- W2891848403 hasRelatedWork W2029419207 @default.
- W2891848403 hasRelatedWork W2040541876 @default.
- W2891848403 hasRelatedWork W2058009067 @default.
- W2891848403 hasRelatedWork W2058803762 @default.
- W2891848403 hasRelatedWork W2062264619 @default.
- W2891848403 hasRelatedWork W2098161468 @default.
- W2891848403 hasRelatedWork W2120717174 @default.
- W2891848403 hasRelatedWork W2126642894 @default.
- W2891848403 hasRelatedWork W2135969256 @default.
- W2891848403 hasRelatedWork W2138039718 @default.
- W2891848403 hasRelatedWork W2462710785 @default.
- W2891848403 hasRelatedWork W2462844398 @default.
- W2891848403 hasRelatedWork W2952246870 @default.
- W2891848403 hasRelatedWork W2960147818 @default.
- W2891848403 hasRelatedWork W3083416721 @default.
- W2891848403 hasRelatedWork W2407485738 @default.
- W2891848403 isParatext "false" @default.
- W2891848403 isRetracted "false" @default.
- W2891848403 magId "2891848403" @default.
- W2891848403 workType "article" @default.